

Chordate Medical in the US – result from the migraine study is being presented

Tomorrow, Saturday, June 17th, coordinating study leader, Dr. Jan Hoffmann from King's College in London, will present the primary parts of the final results from Chordate Medical's pivotal clinical study PM007 at the American Headache Society Scientific Meeting. Chordate's CEO, Anders Weilandt, is present in Austin, Texas.

"It's very exciting, partly because it's the first time the study's final results are being presented at a conference, and partly because it's the first time the company is engaging in this type of activity in the US", says Anders Weilandt.

In addition to Dr. Hoffmann's lecture, Anders Weilandt has meetings with industry professionals and researchers over the weekend. The participants at the conference consist mainly of specialists in headache and migraine, with the majority being from the USA, but also including international visitors.

"The main focus is, of course, the presentation and capturing the expected interest it will generate. It's also important to continue building networks within the industry represented at the conference and the associated exhibition."

For more information, please contact:

Anders Weilandt, CEO

anders.weilandt@chordate.com

Cell: +46 733-874277

About Chordate

Chordate Medical Holding AB (publ) is a medical technology company that has developed, patented and CE-marked a neuromodulation and drug-free treatment technology for chronic migraine and chronic nasal congestion (rhinitis), Kinetic Oscillation Stimulation (K.O.S). The treatment has clinically proven efficacy according to a recent study, and is marketed in Finland, Germany, the UK, Italy, Israel, and Saudi Arabia. Chordate Medical is listed on Nasdaq First North Growth Market Stockholm (ticker: CMH). Read more at www.chordate.com

The company's Certified Adviser on Nasdaq First North Growth Market Stockholm is Västra Hamnen Corporate Finance AB.

N.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail.

Press Release
16 June 2023 16:10:00 CEST

CHORDATE
M E D I C A L

Image Attachments

[Anders Weilandt, Dr Jan Hoffmann](#)

Attachments

[Chordate Medical in the US – result from the migraine study is being presented](#)